Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Prostate Cancer Treatment & Management: Approach Considerations, Localized Prostate Cancer, Management of Advanced and Metastatic Disease

American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium - Page 2 of 7 - Cancer Therapy Advisor

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Advances in the treatment of metastatic prostate cancer: Trends in Cancer

Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC, Latest news for Doctors, Nurses and Pharmacists

Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Prostate cancer - The Lancet

Rucaparib Bests Physician's Choice in Metastatic Castration-Resistant Prostate Cancer - Cancer Therapy Advisor

Cancers, Free Full-Text

Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect

Metastatic Prostate Cancer

PARP Inhibitors - Effective in Men with BRCA-Mutant Prostate Cancer - CancerConnect

𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 on X: ⚡️ Just RELEASED NEJM: Ph 3 trial Rucaparib mCRPC patients w/BRCA1, BRCA2, ATM after 2nd gen ARPI. ✓62 mo rPFS 11.2 mo vs 6.4 mo(Ruc vs